Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include...

Can-Fite BioPharma announced positive Phase IIa results for namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC), meeting its primary safety endpoint with no new safety signals identified. The study enrolled 20 heavily pretreated patients, with 1/3 currently alive at data cutoff. Survival outcomes remain under follow-up and will be rep...

Can-Fite BioPharma announced a 1-for-3,000 reverse stock split of its ordinary shares, approved by shareholders on November 10, 2025, effective January 5, 2026 on the Tel-Aviv Stock Exchange and NYSE American. The reverse split will also adjust the ADS ratio from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, equi...

Can-Fite BioPharma's drug Namodenoson has shown promising results in treating liver cancer, as well as providing protective effects on the heart, liver, and nervous system, unlike traditional chemotherapy. The study highlights Namodenoson's ability to increase adiponectin levels, a key cytokine known to drive multi-organ protective effects.

Can-Fite BioPharma, a biotechnology company, announced that it will present its lead drug candidate Namodenoson, which is in late-stage trials for liver cancer and metabolic disorders, at the upcoming BIO CEO & Investor Conference.